5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.81▼ | 2.83▼ | 2.85▼ | 2.66▲ | 2.49▲ |
MA10 | 2.83▼ | 2.84▼ | 2.79▲ | 2.54▲ | 2.54▲ |
MA20 | 2.84▼ | 2.79▲ | 2.71▲ | 2.43▲ | 2.64▲ |
MA50 | 2.84▼ | 2.67▲ | 2.58▲ | 2.56▲ | 3.15▼ |
MA100 | 2.79▲ | 2.57▲ | 2.47▲ | 2.62▲ | 4.06▼ |
MA200 | 2.72▲ | 2.46▲ | 2.45▲ | 2.87▼ | 4.06▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.006▼ | -0.004▼ | 0.009▲ | 0.056▲ | 0.042▲ |
RSI | 35.349▼ | 54.692▲ | 61.503▲ | 68.576▲ | 50.720▲ |
STOCH | 6.044▼ | 58.337 | 75.832 | 86.308▲ | 32.487 |
WILL %R | -100.000▼ | -38.462 | -33.898 | -16.000▲ | -40.654 |
CCI | -122.010▼ | -13.909 | 55.292 | 182.334▲ | 50.401 |
Monday, September 15, 2025 05:17 AM
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX) ...
|
Thursday, September 11, 2025 09:26 AM
Read the latest analysis on ImmunityBio stock: strong Anktiva NMIBC data but slow sales and valuation concerns.
|
Monday, September 08, 2025 05:53 AM
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA® (nogapendekin alfa ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/09/25 | 2.78 | 2.905 | 2.745 | 2.805 | 10,157,029 |
15/09/25 | 2.62 | 2.75 | 2.58 | 2.74 | 27,014,294 |
12/09/25 | 2.58 | 2.62 | 2.54 | 2.60 | 7,710,724 |
11/09/25 | 2.58 | 2.67 | 2.54 | 2.59 | 9,984,325 |
10/09/25 | 2.56 | 2.58 | 2.49 | 2.57 | 10,381,934 |
09/09/25 | 2.42 | 2.61 | 2.35 | 2.57 | 21,615,870 |
08/09/25 | 2.48 | 2.485 | 2.32 | 2.41 | 11,531,512 |
05/09/25 | 2.41 | 2.45 | 2.37 | 2.40 | 5,889,865 |
04/09/25 | 2.38 | 2.40 | 2.29 | 2.39 | 6,341,027 |
03/09/25 | 2.39 | 2.46 | 2.34 | 2.37 | 6,845,333 |
|
|
||||
|
|
||||
|
|